Emasenyie Isikwei

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 9 papers. Top paper: “Risk factors for hypogammaglobulinemia in chronic lymphocytic leukemia patients treated with anti-CD20 monoclonal antibody-based therapies”.

Risk factors for hypogammaglobulinemia in chronic lymphocytic leukemia patients treated with anti-CD20 monoclonal antibody-based therapies

Journal of Hematopathology(2020)10.1007/s12308-020-00417-5

N/A

0DataRank · unranked

4 citations

Emasenyie Isikwei, Pragya Shrestha, Melissa R. Snyder, Brian Kabat, Kari G. Rabe +4 more

Phase 1 study of pevonedistat (MLN4924) a NEDD8 activating enzyme inhibitor, in combination with temozolomide (TMZ) and irinotecan (IRN) in pediatric patients with recurrent or refractory solid tumors (ADVL1615).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.10019

N/A

0DataRank · unranked

3 citations

Joel M. Reid, Charles G. Minard, Emasenyie Isikwei, Xiaowei Liu, Stacey L. Berg +4 more

Feasibility of pevonedistat combined with azacitidine, fludarabine, cytarabine in pediatric relapsed/refractory AML: Results from COG ADVL1712.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.10018

N/A

0DataRank · unranked

0 citations

Xiaowei Liu, Charles G. Minard, Sarah Menig, Joel M. Reid, Emasenyie Isikwei +6 more

A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-2164

N/A

0DataRank · unranked

72 citations

Elizabeth Fox, Emasenyie Isikwei, Joel M. Reid, Xiaowei Liu, Charles G. Minard +5 more

FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-0873

N/A

0DataRank · unranked

48 citations

Amy Barone, Somak Chatterjee, Pallavi S. Mishra‐Kalyani, Yuan Li Shen, Emasenyie Isikwei +14 more

Feasibility of pevonedistat combined with azacitidine, fludarabine, cytarabine in pediatric relapsed/refractory AML: Results from COG ADVL1712

Pediatric Blood & Cancer(2023)10.1002/pbc.30672

N/A

0DataRank · unranked

3 citations

Xiaowei Liu, Charles G. Minard, Emasenyie Isikwei, Joel M. Reid, Terzah M. Horton +4 more

Data from A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412

(2023)10.1158/1078-0432.c.6532749

N/A

0DataRank · unranked

0 citations

Elizabeth Fox, Emasenyie Isikwei, Joel M. Reid, Xiaowei Liu, Charles G. Minard +5 more

Data from A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412

(2023)10.1158/1078-0432.c.6532749.v1

N/A

0DataRank · unranked

0 citations

Elizabeth Fox, Emasenyie Isikwei, Joel M. Reid, Xiaowei Liu, Charles G. Minard +5 more

Phase 1 study of NEDD8 activating enzyme inhibitor pevonedistat in combination with chemotherapy in pediatric patients with recurrent or refractory solid tumors (ADVL1615)

European Journal of Cancer(2024)10.1016/j.ejca.2024.114241

N/A

0DataRank · unranked

15 citations

Joel M. Reid, Charles G. Minard, Sarah E. Woodfield, Kristina Z. Denic, Emasenyie Isikwei +7 more